Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AG-RUL
- Development stage
- Preclinical
- Lead developer
- AmeboGenesis
- Modality
- Whole Cell Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
01
Overview
AG-RUL (AmeboGenesis Raw Unprocessed Lysate) is an emerging biotechnology platform being developed by MygoGenesis and its subsidiary AmeboGenesis. It is designed for the rapid detection and potential removal of bacterial endotoxins (lipopolysaccharides) and other bacterial molecular signals from human biological fluids, such as serum and cerebrospinal fluid. Built on the company's proprietary Mygotic Process™, which generates sustainable and scalable supplies of amebocytes, AG-RUL harnesses the sensitivity of ancient innate immune systems to target endotoxins. The technology is proposed for applications in managing sepsis, inflammatory diseases, and antimicrobial resistance/infection control.
- Other names
- AmeboGenesis Raw Unprocessed Lysate
Beyond the preview
Go deeper on AG-RUL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AG-RUL.